Antiandrogenic properties of the dienogest-containing oral contraceptive Valette®

Drugs of Today

Volumn 35, Issue SUPPL. C, 1999, Pages 69-78

  Moore, Claudia ^a   Luderschmidt, C ^b   Moltz, L ^c   Oettel, M ^a   Klinger, G ^d   Schreiber, G ^d  

^a BAYER PHARMA AG   (Germany)

^b Red Cross Hospital   (Germany)

^c Clinic of Obstetrics and Gynecology   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIANE; DIENOGEST; DIENOGEST PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; LOW DOSE ORAL CONTRACEPTIVE; METRIBOLONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ACNE; ANDROGEN BLOOD LEVEL; ANDROGEN RELEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HYPOPHYSIS FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PUNCH BIOPSY; RADIOIMMUNOASSAY; REVIEW; TREATMENT OUTCOME;

EID: 0032810257     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Oettel, M., Carol, W., Elger, W. et al. A 19-norprogestin without a 17α-ethinyl group. II: Dienogest from a pharmacodynamic point of view. Drugs of Today 1995, 31: 517-36.
2. Juchem, M., Schaffrath, M., Pollow, K., Hoffmann, G., Kaufmann, G. Dienogest: Bindungsstudien an verschiedenen Rezeptor- und Serumproben. In: Dienogest - Präklinik und Klinik eines Gestagens. Teichmann A.T. (Ed.). W. de Gruyter: Berlin/New York: 1995, 119-33.
3. Pardridge, W.M. Transport of protein-bound hormones into tissues in vivo. Endocrin Rev 1981, 2: 103-23.
4. Oettel, M., Elger, W., Ernst, M. et al. Experimentelle Endokrinpharmakologie von Dienogest. In: Dienogest - Präklinik und Klinik eines Gestagens. Teichmann A.T. (Ed.). W. de Gruyter: Berlin/New York: 1995, 11-21.
5. Oettel, M., Bervoas-Martin, B., Elger, W. et al. A 19-norprogestin without a 17α-ethinyl group. I: Dienogest from a pharmacokinetic point of view. Drugs of Today 1995, 31: 499-516.
6. Nilsson, B., von Schoultz, B. Binding of levonorgestrel, norethisterone and desogestrel to human sex hormone binding globulin and influence on free testosterone levels. Gynecol Obstet Invest 1989, 27: 151-4.
7. Oettel, M., Carol, W., Gräser, T. et al. Der Einfluß einer Ethinylestradiol-Dienogest-Kombination auf die Serum-Androgen-Konzentrationen. Zentralbl Gynäkol 1997, 119: 597-606.
8. Moore C., Walter F., Klinger G., Carol W. Der Einfluß von Dienogest auf die Ovulation junger Frauen und auf ausgewählte endokrinologische Parameter. In: Dienogest - Präklinik und Klinik eines neuen Gestagens. Teichmann A.T. (Ed.). Walter de Gruyter Verlag: Berlin 1995, 161-9.
9. Van der Vange, N., Blankenstein, M.A., Klosterboer, H.J., Haspels, A.A., Thijssen, J.H.H. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 1990, 41: 345-52.
10. Luderschmidt, C., Plewig, G. Differente Therapie der Acne vulgaris. Dt Ärztebl 1986, 42: 258.
11. Fern, M., Rose, D.P., Fern, E.B. Effect of oral contraceptives on plasma androgenic steroids and their precursors. Obstet Gynecol 1978, 51: 541-4.
12. Luderschmidt, C. Hormonal control of androgenic disorders in women. In: Extragenital Effects of Oral Contraceptives. Elstein, M. (Ed.) The Parthenon Publishing Group: Carnforth 1997, 45-51.
13. Randall, V.A. Androgens and human hair growth. Clin Endocrinol 1994, 40: 439-57.
14. Burkman, R.T. The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 1995, 98 (Suppl. 1A): 130S-6S.
15. Kuhl, H., Jung-Hoffmann, C., Storch, A., Fitzner, M., Rühl, E. New aspects on the mechanism of action of contraceptive steroids - recent pharmacokinetic studies of low dose formulations. Adv Contracept 1991, 7 (Suppl. 3): 149-63.
16. Schürenkämper P., Lisse, K. Effects of the new progestagen STS 557 on the biosynthesis of steroids in tissue slices of the human ovary. Exp Clin Endocrinol 1985, 86: 185-9.
17. Kuhl, H. Comparative pharmacology of newer progestogens. Drugs 1996, 51: 188-215.
18. Vermeulen, A., Rubens, R. Effect of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids. Contraception 1988, 38: 419-28.
19. Derman, R.J. Androns and oral contraception. In: Androgenic Disorders. Redmond G.P. (Ed.). Raven Press: New York 1995, 301-323.
20. El Makhzangy, M.N., Wynn, V., Lawrence, D.M. Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids. Clin Endocrinol 1979, 10: 39-45.
21. Wiegratz, I., Jung-Hoffmann, C., Kuhl, H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception 1995, 51: 341-6.
22. Cullberg, G., Dovré, P.A., Lindstedt, G., Steffensen K. On the use of plasma proteins as indicator of the metabolic effects of combined oral contraceptives. Acta Obstet Gynecol Scand Suppl 1982, 11: 47-54.
23. Coenen, C.M.H., Thomas, C.M.G., Borm, G.F., Hollanders, J.M.G., Rolland, R. Changes in androgens during treatment with four low-dose contraceptives. Contraception 1996, 53: 171-6.
24. Cassidenti, D.L., Paulson, R.J., Serafini, P., Stanczyk, F.Z., Lobo, R.A. Effects of sex steroids on skin 5α-reductase activity in vitro. Obstet Gynecol 1991, 78:103-107.